Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177676 | 1.00 | KLK7 (0.51) | KLK7KLK5CASP1SYKCTSK | |
| SCHEMBL29400686 | 0.92 | KLK7 (0.60) | KLK7KLK5CASP1SYKCTSK | |
| SCHEMBL2777934 | 0.90 | SYK (0.46) | KLK7KLK5CASP1SYKCTSK | |
| SCHEMBL29401961 | 0.89 | CASP1 (0.51) | KLK7KLK5CASP1CTSKCTSL | |
| SCHEMBL8059266 | 0.88 | KLK7 (0.55) | KLK7KLK5CASP1SYKCTSK | |
| SCHEMBL3873338 | 0.88 | KLK7 (0.55) | KLK7KLK5CASP1SYKCTSK | |
| SCHEMBL22657970 | 0.86 | CASP1 (0.60) | CASP1 | |
| SCHEMBL22657972 | 0.86 | CASP1 (0.60) | CASP1 | |
| SCHEMBL45092 | 0.86 | CTSK (0.47) | CASP1CTSKCTSLCTSBCTSS | |
| SCHEMBL7327877 | 0.85 | CTSK (0.54) | CASP1SYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AZEVAN PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008034032-A2 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7268125-B2 | β-lactamyl vasopressin V1a antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AZEVAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AZEVAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1434763-A2 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | Serenix Pharmaceuticals, LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | KLK7 798/4885KLK5 402/4885CASP1 667/4885 |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | KLK7 1308/4885KLK5 728/4885CASP1 1836/4885 |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AVPR1A, AVPR2, AVPR1B | KLK7 733/4885KLK5 466/4885CASP1 2310/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | KLK7 2818/4885KLK5 2631/4885CASP1 3329/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | KLK7 2207/4885KLK5 813/4885CASP1 3550/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | KLK7 2352/4885KLK5 2841/4885CASP1 1603/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | KLK7 2207/4885KLK5 813/4885CASP1 3550/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | KLK7 798/4885KLK5 402/4885CASP1 667/4885 |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AVPR1A, AVPR2, AVPR1B | KLK7 1287/4885KLK5 1040/4885CASP1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.